{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:41:57Z","timestamp":1788950517009,"version":"build-2803163510"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["17\/148\/03"],"award-info":[{"award-number":["17\/148\/03"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.eclinm.2023.102073","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T14:54:36Z","timestamp":1688223276000},"page":"102073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7855-0991","authenticated-orcid":false,"given":"Shuo","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"McLellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pidduck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nia","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian P.T.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5561-4366","authenticated-orcid":false,"given":"Yoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alane","family":"Izu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabir A.","family":"Madhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Mulholland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4885-9848","authenticated-orcid":false,"given":"Beth","family":"Temple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6324-6559","authenticated-orcid":false,"given":"Merryn","family":"Voysey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.eclinm.2023.102073_bib1","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15","volume":"6","author":"Wahl","year":"2018","journal-title":"Lancet Glob Health"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102073_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000348","article-title":"Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project","volume":"7","author":"Johnson","year":"2010","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102073_bib3","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/S2214-109X(16)30306-0","article-title":"Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis","volume":"5","author":"Shiri","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102073_bib4","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1080\/21645515.2021.1874219","article-title":"Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine (PNEUMOSIL\u00ae)","volume":"17","author":"Alderson","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.eclinm.2023.102073_bib5","series-title":"Considerations for pneumococcal conjugate vaccine (PCV) product choice","author":"World Health Organization","year":"2021"},{"issue":"08","key":"10.1016\/j.eclinm.2023.102073_bib6","first-page":"85","volume":"94","year":"2019"},{"issue":"19","key":"10.1016\/j.eclinm.2023.102073_bib7","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1016\/j.vaccine.2007.01.119","article-title":"Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies","volume":"25","author":"Siber","year":"2007","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102073_bib8","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-0377","article-title":"Efficacy and effectiveness of the PCV-10 and PCV-13 vaccines against invasive pneumococcal disease","volume":"145","author":"Berman-Rosa","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.eclinm.2023.102073_bib9","series-title":"Pneumococcal conjugate vaccine (PCV) review of impact evidence (PRIME): summary of findings from systematic review","author":"Cohen","year":"2017"},{"issue":"16","key":"10.1016\/j.eclinm.2023.102073_bib10","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.vaccine.2021.02.043","article-title":"Effect of a 2+1 schedule of ten-valent versus 13-valent pneumococcal conjugate vaccine on pneumococcal carriage: results from a randomised controlled trial in Vietnam","volume":"39","author":"Temple","year":"2021","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102073_bib11","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/cid\/ciy743","article-title":"Safety and immunogenicity of pneumococcal conjugate vaccines in a high-risk population: a randomized controlled trial of 10-valent and 13-valent pneumococcal conjugate vaccine in Papua New Guinean infants","volume":"68","author":"Pomat","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102073_bib12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/cix895","article-title":"Serotype-specific correlates of protection for pneumococcal carriage: an analysis of immunity in 19 countries","volume":"66","author":"Voysey","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"16","key":"10.1016\/j.eclinm.2023.102073_bib13","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting Items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102073_bib14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2023.102073_bib15","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2023.102073_bib16","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102073_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.eclinm.2023.102073_bib18","series-title":"Network meta-analysis. Meta-analysis with R","first-page":"187","author":"Schwarzer","year":"2015"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102073_bib19","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Res Synth Methods"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102073_bib20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/INF.0b013e31827b478d","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India","volume":"32","author":"Amdekar","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102073_bib21","article-title":"Correction to lancet infect dis 2020; published online Aug 25","volume":"20","author":"Anonymous","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"16","key":"10.1016\/j.eclinm.2023.102073_bib22","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.vaccine.2021.03.032","volume":"39","author":"Beissbarth","year":"2021","journal-title":"Vaccine"},{"issue":"4 Suppl","key":"10.1016\/j.eclinm.2023.102073_bib23","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/INF.0b013e318199f901","article-title":"The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV\/Hib and poliovirus vaccines: assessment of immunogenicity","volume":"28","author":"Bermal","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102073_bib24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/INF.0b013e3181f2da06","article-title":"Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV\/Hib and poliovirus vaccines","volume":"30","author":"Bermal","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102073_bib25","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1542\/peds.2009-1405","article-title":"Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine","volume":"125","author":"Bryant","year":"2010","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102073_bib26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.vaccine.2018.07.023","article-title":"Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: results from a phase II, randomised, multicentre study","volume":"37","author":"Carmona Martinez","year":"2019","journal-title":"Vaccine"},{"issue":"41","key":"10.1016\/j.eclinm.2023.102073_bib27","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1016\/j.vaccine.2011.06.056","article-title":"The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A","volume":"29","author":"Cooper","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102073_bib28","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/cid\/ciaa083","article-title":"Carrier-induced hyporesponsiveness to pneumococcal conjugate vaccines: unraveling the influence of serotypes, timing, and previous vaccine dose","volume":"72","author":"Dagan","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"36","key":"10.1016\/j.eclinm.2023.102073_bib29","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1016\/j.vaccine.2016.06.075","article-title":"Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration","volume":"34","author":"Dagan","year":"2016","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102073_bib30","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.vaccine.2016.12.052","article-title":"PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children","volume":"35","author":"Dagan","year":"2017","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102073_bib31","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/infdis\/jiu576","article-title":"Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae","volume":"211","author":"Dagan","year":"2015","journal-title":"J\u00a0Infect Dis"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102073_bib32","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/cid\/cit428","article-title":"Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial","volume":"57","author":"Dagan","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102073_bib33","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1128\/CVI.00062-10","article-title":"Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers","volume":"17","author":"Esposito","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"35","key":"10.1016\/j.eclinm.2023.102073_bib34","doi-asserted-by":"crossref","first-page":"6042","DOI":"10.1016\/j.vaccine.2011.06.026","volume":"29","author":"Gimenez-Sanchez","year":"2011","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.eclinm.2023.102073_bib35","doi-asserted-by":"crossref","first-page":"9675","DOI":"10.1016\/j.vaccine.2011.10.012","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants","volume":"29","author":"Grimprel","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102073_bib36","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.vaccine.2011.12.054","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan","volume":"30","author":"Huang","year":"2012","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102073_bib37","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/CVI.00172-14","article-title":"Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization","volume":"21","author":"Juergens","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"25","key":"10.1016\/j.eclinm.2023.102073_bib38","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1016\/j.vaccine.2010.04.008","article-title":"Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany","volume":"28","author":"Kieninger","year":"2010","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102073_bib39","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1097\/INF.0b013e31822a8541","article-title":"Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants","volume":"30","author":"Kim","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102073_bib40","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/INF.0b013e3182748bb6","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to Korean children receiving routine pediatric vaccines","volume":"32","author":"Kim","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102073_bib41","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/INF.0b013e3182323ac2","article-title":"Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants","volume":"31","author":"Knuf","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102073_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-007247","article-title":"Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial","volume":"5","author":"Leach","year":"2015","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102073_bib43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12887-021-02552-z","article-title":"Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial","volume":"21","author":"Leach","year":"2021","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.eclinm.2023.102073_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2021.100086","article-title":"Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial","volume":"7","author":"Leach","year":"2021","journal-title":"Vaccine X"},{"key":"10.1016\/j.eclinm.2023.102073_bib45","first-page":"27","article-title":"Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials","volume":"27","author":"Leach","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eclinm.2023.102073_bib46","first-page":"84","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines to infants in Korea","volume":"99","author":"Lee","year":"2010","journal-title":"Acta Paediatr Int J Paediatr"},{"key":"10.1016\/j.eclinm.2023.102073_bib47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s41479-017-0044-z","article-title":"Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea","volume":"9","author":"Lehmann","year":"2017","journal-title":"Pneumonia"},{"issue":"Supplement 1","key":"10.1016\/j.eclinm.2023.102073_bib48","first-page":"603","article-title":"Immunogenicity and memory B cell response following alternative pneumococcal vaccination strategies in Vietnam","volume":"46","author":"Licciardi","year":"2016","journal-title":"Eur J Immunol"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102073_bib49","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S1473-3099(20)30775-1","article-title":"Immunogenicity of alternative ten-valent pneumococcal conjugate vaccine schedules in infants in Ho Chi Minh City, Vietnam: results from a single-blind, parallel-group, open-label, randomised, controlled trial","volume":"21","author":"Licciardi","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102073_bib50","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S1473-3099(20)30289-9","article-title":"Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial","volume":"20","author":"Madhi","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"19","key":"10.1016\/j.eclinm.2023.102073_bib51","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.vaccine.2017.03.071","article-title":"Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: a phase 2, randomized, controlled, observer-blind study","volume":"35","author":"Odutola","year":"2017","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.eclinm.2023.102073_bib52","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1016\/j.vaccine.2019.03.033","article-title":"Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - a phase II, randomised, observer-blind study in Gambian infants","volume":"37","author":"Odutola","year":"2019","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102073_bib53","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/INF.0b013e3182906499","article-title":"Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United States","volume":"32","author":"Payton","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.eclinm.2023.102073_bib54","first-page":"3","article-title":"Safety and immunogenicity of pneumococcal conjugate vaccines in a high-risk population: a randomised controlled trial of 10-valent and 13-valent PCV in Papua New Guinean infants","volume":"3","author":"Pomat","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"Supplement 1","key":"10.1016\/j.eclinm.2023.102073_bib55","article-title":"Immunogenicity of the booster dose of 2 investigational protein- based pneumococcal vaccine formulations in toddlers: a phase ii randomized trial","volume":"3","author":"Prymula","year":"2016","journal-title":"Open Forum Infect Dis Conf"},{"issue":"Supplement 1","key":"10.1016\/j.eclinm.2023.102073_bib56","article-title":"Safety and reactogenicity of the booster dose of 2 investigational protein-based pneumococcal vaccine formulations in toddlers: a phase ii randomized trial","volume":"3","author":"Prymula","year":"2016","journal-title":"Open Forum Infect Dis Conf"},{"issue":"35 Pt B","key":"10.1016\/j.eclinm.2023.102073_bib57","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1016\/j.vaccine.2017.07.008","article-title":"Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: results from a randomized phase II study in infants","volume":"35","author":"Prymula","year":"2017","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102073_bib58","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1097\/INF.0b013e3181faa6be","article-title":"Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102073_bib59","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1473-3099(18)30734-5","article-title":"Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial","volume":"19","author":"Temple","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102073_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019795","article-title":"Evaluation of different infant vaccination schedules incorporating pneumococcal vaccination (The Vietnam Pneumococcal Project): protocol of a randomised controlled trial","volume":"8","author":"Temple","year":"2018","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102073_bib61","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/INF.0000000000000819","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with DTaP vaccine in healthy infants in Japan","volume":"34","author":"Togashi","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102073_bib62","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1097\/INF.0b013e31821a0614","volume":"30","author":"van den Bergh","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102073_bib63","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1097\/INF.0000000000001170","article-title":"Immunogenicity, safety and reactogenicity of a booster dose of the 10-valent pneumococcal nontypeable H. Influenzae protein D conjugate vaccine coadministered with DTPa-IPV-hib in Dutch children: a randomized controlled trial","volume":"35","author":"van den Bergh","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102073_bib64","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1093\/cid\/cis922","article-title":"Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial","volume":"56","author":"van den Bergh","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102073_bib65","first-page":"4","article-title":"Immunogenicity and immune memory after a pneumococcal polysaccharide vaccine booster in a high-risk population primed with 10-valent or 13-valent pneumococcal conjugate vaccine: a randomized controlled trial in Papua","volume":"7","author":"van den Biggelaar","year":"2019","journal-title":"New Guinean Children"},{"issue":"4 Suppl","key":"10.1016\/j.eclinm.2023.102073_bib66","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/INF.0b013e318199f8ef","article-title":"Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine","volume":"28","author":"Vesikari","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"52","key":"10.1016\/j.eclinm.2023.102073_bib67","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.1016\/j.vaccine.2012.10.040","article-title":"A\u00a0phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil","volume":"30","author":"Weckx","year":"2012","journal-title":"Vaccine"},{"issue":"4 Suppl","key":"10.1016\/j.eclinm.2023.102073_bib68","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1097\/INF.0b013e318199f609","article-title":"Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines","volume":"28","author":"Wysocki","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102073_bib69","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1542\/peds.2009-3027","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers","volume":"126","author":"Yeh","year":"2010","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102073_bib70","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/INF.0000000000002458","article-title":"Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine administered in a 3\u00a0+ 1 versus 2\u00a0+ 1 dose schedule among infants in China","volume":"38","author":"Zhu","year":"2019","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102073_bib71","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/INF.0000000000001248","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine compared with 7-valent pneumococcal conjugate vaccine among healthy infants in China","volume":"35","author":"Zhu","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"Supplement 1","key":"10.1016\/j.eclinm.2023.102073_bib72","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/ofid\/ofx163.1402","volume":"4","author":"De Los Santos","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"46","key":"10.1016\/j.eclinm.2023.102073_bib73","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1016\/j.vaccine.2013.06.049","article-title":"Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain","volume":"31","author":"Diez-Domingo","year":"2013","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102073_bib74","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/INF.0b013e31824b972b","article-title":"13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety","volume":"31","author":"Martinon-Torres","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102073_bib75","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/INF.0b013e318233049d","article-title":"Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada","volume":"31","author":"Vanderkooi","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102073_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040385","article-title":"A\u00a0novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS One"},{"issue":"SUPPL 1","key":"10.1016\/j.eclinm.2023.102073_bib77","article-title":"Phase 3 study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114 in healthy infants, children, and adolescents (PNEU-PLAN)","volume":"8","author":"Banniettis","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"SUPPL 1","key":"10.1016\/j.eclinm.2023.102073_bib78","article-title":"A\u00a0phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114 and prevnar 13TM with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)","volume":"8","author":"Bili","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102073_bib79","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012488","article-title":"Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China","volume":"6","author":"Chen","year":"2016","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102073_bib80","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1473-3099(20)30735-0","article-title":"Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in the Gambia: a phase 3, randomised, double-blind, non-inferiority trial","volume":"21","author":"Clarke","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102073_bib81","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.vaccine.2019.08.072","article-title":"Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in the Gambia-Results of a phase 1\/2 randomized, double-blinded, controlled trial","volume":"38","author":"Clarke","year":"2020","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102073_bib82","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/infdis\/174.6.1271","article-title":"Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine","volume":"174","author":"Dagan","year":"1996","journal-title":"J\u00a0Infect Dis"},{"issue":"45","key":"10.1016\/j.eclinm.2023.102073_bib83","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1016\/j.vaccine.2018.02.113","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants","volume":"36","author":"Greenberg","year":"2018","journal-title":"Vaccine"},{"issue":"32 Pt B","key":"10.1016\/j.eclinm.2023.102073_bib84","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1016\/j.vaccine.2018.05.027","article-title":"Safety and immunogenicity of the Cuban heptavalent pneumococcal conjugate vaccine in healthy infants. Results from a double-blind randomized control trial Phase I","volume":"36","author":"Martinez","year":"2018","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102073_bib85","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/INF.0000000000002765","article-title":"A\u00a0phase II trial of safety, tolerability and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in healthy infants","volume":"39","author":"Platt","year":"2020","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102073_bib86","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/21645515.2019.1568159","article-title":"A\u00a0dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants","volume":"15","author":"Rupp","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"SUPPL 1","key":"10.1016\/j.eclinm.2023.102073_bib87","doi-asserted-by":"crossref","first-page":"S637","DOI":"10.1093\/ofid\/ofaa439.1421","article-title":"Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in healthy infants in the United States","volume":"7","author":"Senders","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102073_bib88","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/INF.0000000000003277","article-title":"Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy infants in the United States","volume":"40","author":"Senders","year":"2021","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102073_bib89","first-page":"265","article-title":"Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6\u201310 weeks: a randomized double-blind active-controlled trial","volume":"63","author":"Shin","year":"2020","journal-title":"Korean J Pediatr"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102073_bib90","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.4161\/hv.28642","article-title":"Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine","volume":"10","author":"Thisyakorn","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.eclinm.2023.102073_bib91","article-title":"Immunogenicity and safety of a novel 13-valent pneumococcal vaccine in healthy Chinese infants and toddlers","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.eclinm.2023.102073_bib92","first-page":"10","article-title":"Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2\u00a0+ 1 schedule to healthy infants in the Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial","volume":"10","author":"Adigweme","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102073_bib93","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.vaccine.2022.10.072","article-title":"A\u00a0phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)","volume":"41","author":"Bili","year":"2023","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.eclinm.2023.102073_bib94","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1016\/j.vaccine.2022.09.003","volume":"40","author":"Banniettis","year":"2022","journal-title":"Vaccine"},{"issue":"Supplement 2","key":"10.1016\/j.eclinm.2023.102073_bib95","article-title":"A\u00a0phase 3, multicenter, randomised, doubleblind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-DOSE regimen of V114 in healthy infants (PNEU-PED)","volume":"107","author":"Lupinacci","year":"2022","journal-title":"Arch Dis Child"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102073_bib96","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.vaccine.2022.12.054","article-title":"A\u00a0phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)","volume":"41","author":"Lupinacci","year":"2023","journal-title":"Vaccine"},{"issue":"34","key":"10.1016\/j.eclinm.2023.102073_bib97","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1016\/j.vaccine.2016.06.038","article-title":"The impact of administration of conjugate vaccines containing cross reacting material on Haemophilus influenzae type b antibody responses in infants: a systematic review and meta-analysis of randomised controlled trials","volume":"34","author":"Voysey","year":"2016","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102073_bib98","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S2352-4642(18)30168-8","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study","volume":"2","author":"Pichichero","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102073_bib99","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2214-109X(18)30422-4","article-title":"Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis","volume":"7","author":"Chen","year":"2019","journal-title":"Lancet Glob Health"},{"issue":"38","key":"10.1016\/j.eclinm.2023.102073_bib100","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1016\/j.vaccine.2018.07.078","article-title":"How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country","volume":"36","author":"Casta\u00f1eda-Orjuela","year":"2018","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.eclinm.2023.102073_bib101","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1016\/j.vaccine.2011.04.111","article-title":"Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina","volume":"29","author":"Urue\u00f1a","year":"2011","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.eclinm.2023.102073_bib102","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1016\/j.vaccine.2019.06.015","article-title":"An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand","volume":"37","author":"Dilokthornsakul","year":"2019","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102073_bib103","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1164\/rccm.201212-2277OC","article-title":"Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults","volume":"187","author":"Ferreira","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102073_bib104","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/mi.2016.71","article-title":"Agglutination by anti-capsular polysaccharide antibody is associated with protection against experimental human pneumococcal carriage","volume":"10","author":"Mitsi","year":"2017","journal-title":"Mucosal Immunol"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102073_bib105","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1164\/rccm.201503-0542OC","article-title":"First human challenge testing of a pneumococcal vaccine. Double-blind randomized controlled trial","volume":"192","author":"Collins","year":"2015","journal-title":"Am J Respir Crit Care Med"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702300250X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702300250X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:21:34Z","timestamp":1762899694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258953702300250X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":105,"alternative-id":["S258953702300250X"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102073","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102073"}}